Physician profile
John B Siebenlist
NPI 1164476909
$4,895.87
in general payments reported to CMS, 2019-2025
29 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $224 · 2021: $227 · 2022: $358 · 2023: $1,236 · 2024: $1,226 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.72 |
| Education | $160.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $968.34 | 2019-2025 | Tremfya |
| Abbvie INC. | $864.96 | 2019-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $449.94 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $402.75 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $363.61 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $264.64 | 2020-2025 | Ilumya |
| Galderma Laboratories, L.P. | $212.24 | 2020-2025 | Nemluvio |
| Genzyme Corporation | $155.93 | 2021-2024 | |
| Incyte Corporation | $132.65 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $131.03 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $115.25 | 2019-2025 | |
| Pfizer INC. | $106.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.81 | 2023-2024 | Spevigo |
| Amgen INC. | $96.21 | 2022-2024 | Otezla |
| Organogenesis INC. | $78.79 | 2023-2025 | Affinity, Puraply |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $75.71 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $61.58 | 2025 | |
| Genentech USA, INC. | $43.85 | 2021-2024 | Actemra |
| Ucb, INC. | $42.90 | 2021-2025 | Bimzelx |
| Dermira, INC. | $36.55 | 2019 | |
| Celgene Corporation | $28.35 | 2019 | |
| Janssen Scientific Affairs, LLC | $26.13 | 2020 | |
| Journey Medical Corporation | $24.25 | 2024 | |
| Leo Pharma INC. | $23.60 | 2025 | Anzupgo |
| Vyne Pharmaceuticals INC. | $22.93 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $21.79 | 2019 | |
| Merz North America, INC. | $21.77 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.50 | 2023 | Valchlor |
| Strata Skin Sciences, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Siebenlist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.